Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: the EMBRACE study

By Gauthier Serge  

Current Medical Research and Opinion, Vol. 29, Iss. 8, 2013-08 ,pp. : 989-1000

Informa Healthcare

Access to resources Recommend Favorite

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer’s disease: a post hoc analysis

By Farlow Martin R.   Alva Gus   Meng Xiangyi   Olin Jason T.  

Current Medical Research and Opinion, Vol. 26, Iss. 2, 2010-02 ,pp. : 263-269

Informa Healthcare

Access to resources Recommend Favorite

Patient and caregiver outcomes after 6 ± 1.5-months of rivastigmine therapy for mild-to-moderate Alzheimer's disease: the Belgian FExT study

By Mets Tony   Vandewoude Maurits   Jacquy Jean   Deblander Anne   MacDonald Karen   Sloesen Anne   Abraham Ivo    

Current Medical Research and Opinion, Vol. 23, Iss. 10, 2007-10 ,pp. : 2485-2501

Informa Healthcare

Access to resources Recommend Favorite

A Retrospective Comparison of Older and Younger Adults Undergoing Early Laparoscopic Cholecystectomy for Mild to Moderate Calculous Cholecystitis

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 63, Iss. 5, 2015-05 ,pp. : 1010-1016

John Wiley & Sons Inc

Access to resources Recommend Favorite

Measuring social participation: reliability of the LIFE-H in older adults with disabilities

By Noreau Luc   Desrosiers Johanne   Robichaud Line   Fougeyrollas Patrick   Rochette Annie   Viscogliosi Chantal  

Disability and Rehabilitation, Vol. 26, Iss. 6, 2004-03 ,pp. : 346-352

Informa Healthcare

Access to resources Recommend Favorite